Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT

Phase I: To Determine the Maximum Tolerated Dose (MTD) Clinical Trial

Official title: A Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer

Status Terminated

Clinical Trial Summary

To evaluate the efficacy of preoperative S-1/oxaliplatin/RT in locally advanced gastric cancer

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Phase I: To Determine the Maximum Tolerated Dose (MTD)
• Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin

• NCT number: NCT01106066
• Study type: Interventional
• Source: Samsung Medical Center
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: March 2009
• Completion date: November 2012